O	0	9	Influence
O	10	12	of
B-intervention	13	23	zoledronic
I-intervention	24	28	acid
O	29	31	on
O	32	44	disseminated
O	45	50	tumor
O	51	56	cells
O	57	59	in
O	60	67	primary
O	68	74	breast
O	75	81	cancer
O	82	90	patients
O	90	91	.

O	92	95	The
O	96	104	presence
O	105	107	of
O	108	120	disseminated
O	121	126	tumor
O	127	132	cells
O	133	134	(
O	134	138	DTCs
O	138	139	)
O	140	142	in
O	143	147	bone
O	148	154	marrow
O	155	157	of
O	158	166	patients
O	167	171	with
O	172	177	early
O	178	184	breast
O	185	191	cancer
O	192	193	(
O	193	196	EBC
O	196	197	)
O	198	201	has
O	202	206	been
O	207	217	correlated
O	218	222	with
O	223	232	increased
O	233	237	risk
O	238	240	of
O	241	251	metastatic
O	252	259	disease
O	260	262	or
O	263	275	locoregional
O	276	283	relapse
O	283	284	.

O	285	295	Zoledronic
O	296	300	acid
O	301	302	(
O	302	305	ZOL
O	305	306	)
O	307	316	treatment
O	317	320	has
O	321	328	reduced
O	329	333	DTCs
O	334	336	in
O	337	340	the
O	341	345	bone
O	346	352	marrow
O	353	355	of
O	356	364	patients
O	365	369	with
O	370	373	EBC
O	374	376	in
O	377	384	several
O	385	392	studies
O	392	393	.

O	394	398	This
O	399	409	controlled
O	410	415	study
O	416	422	sought
O	423	425	to
O	426	433	confirm
O	434	439	these
O	440	452	observations
O	452	453	.

B-eligibility	454	462	Patients
I-eligibility	463	467	with
I-eligibility	468	471	EBC
I-eligibility	472	475	and
I-eligibility	476	479	DTC
I-eligibility	479	480	-
I-eligibility	480	488	positive
I-eligibility	489	493	bone
I-eligibility	494	500	marrow
O	501	505	were
O	506	516	randomized
O	517	518	(
O	518	519	N
O	520	521	=
B-total-participants	522	524	96
O	524	525	)
O	526	528	to
O	529	538	treatment
O	539	543	with
O	544	547	ZOL
O	548	552	plus
O	553	561	adjuvant
O	562	570	systemic
O	571	578	therapy
O	579	581	or
B-control	582	590	adjuvant
I-control	591	599	systemic
I-control	600	607	therapy
I-control	608	613	alone
O	613	614	.

O	615	618	The
O	619	625	change
O	626	628	in
O	629	632	DTC
O	633	640	numbers
O	641	643	at
O	644	646	12
O	647	653	months
O	654	660	versus
O	661	669	baseline
O	670	673	was
O	674	682	measured
O	682	683	.

O	684	687	DTC
O	687	688	-
O	688	696	positive
O	697	705	patients
O	706	713	treated
O	714	718	with
O	719	722	ZOL
O	723	727	were
O	728	732	more
B-outcome	733	739	likely
I-outcome	740	742	to
I-outcome	743	749	become
I-outcome	750	753	DTC
I-outcome	753	754	-
I-outcome	754	762	negative
O	763	768	after
O	769	771	12
O	772	778	months
O	779	781	of
O	782	791	treatment
O	792	800	compared
O	801	805	with
O	806	809	the
O	810	818	controls
O	819	820	(
B-iv-bin-percent	820	822	67
I-iv-bin-percent	822	823	%
O	824	830	versus
B-cv-bin-percent	831	833	35
I-cv-bin-percent	833	834	%
O	834	835	;
O	836	837	P
O	838	839	=
O	840	841	0
O	841	842	.
O	842	845	009
O	845	846	)
O	846	847	.

O	848	850	At
O	851	853	12
O	854	860	months
O	860	861	,
B-outcome	862	865	DTC
I-outcome	866	872	counts
O	873	882	decreased
O	883	885	to
O	886	887	a
O	888	892	mean
O	893	895	of
B-iv-cont-mean	896	897	0
I-iv-cont-mean	897	898	.
I-iv-cont-mean	898	899	5
O	900	901	±
B-iv-cont-sd	902	903	0
I-iv-cont-sd	903	904	.
I-iv-cont-sd	904	905	8
I-iv-cont-sd	906	910	DTCs
O	911	913	in
O	914	917	the
O	918	921	ZOL
O	922	927	group
O	928	931	and
O	932	934	to
B-cv-cont-mean	935	936	0
I-cv-cont-mean	936	937	.
I-cv-cont-mean	937	938	9
O	939	940	±
B-cv-cont-sd	941	942	0
I-cv-cont-sd	942	943	.
I-cv-cont-sd	943	944	8
I-cv-cont-sd	945	949	DTCs
O	950	952	in
O	953	956	the
O	957	964	control
O	965	970	group
O	970	971	.

O	972	974	In
O	975	983	addition
O	983	984	,
O	985	988	ZOL
O	989	992	was
O	993	1002	generally
B-outcome	1003	1007	well
I-outcome	1008	1017	tolerated
O	1017	1018	.

O	1019	1028	Treatment
O	1029	1033	with
O	1034	1037	ZOL
O	1038	1046	improves
B-outcome	1047	1058	elimination
I-outcome	1059	1061	of
I-outcome	1062	1066	DTCs
O	1066	1067	.

O	1068	1075	Further
O	1076	1083	studies
O	1084	1087	are
O	1088	1094	needed
O	1095	1097	to
O	1098	1107	determine
O	1108	1115	whether
O	1116	1119	the
O	1120	1129	reduction
O	1130	1132	in
O	1133	1137	DTCs
O	1138	1140	by
O	1141	1144	ZOL
O	1145	1153	provides
O	1154	1162	clinical
O	1163	1170	benefit
O	1170	1171	.
